U.S. Metals and Mining Stock News

Clover Health Investments FY 2025 Earnings Snapshot Clover Health Investments (CLOV) has wrapped up FY 2025 with Q4 revenue of US$487.7 million and a basic EPS loss of US$0.10, alongside a trailing 12 month revenue figure of about US$1.9 billion and a basic EPS loss of US$0.17 that keeps the company in loss making territory. Over the past few quarters, the company has seen quarterly revenue move from US$462.3 million in Q1 2025 to US$496.7 million in Q3 2025 before ending the year at US$487.7...

Autodesk (ADSK) has wrapped up FY 2026 with Q4 revenue of US$1.96b and basic EPS of US$1.49, alongside trailing twelve month revenue of US$7.21b and EPS of US$5.28, setting a clear reference point for how the business is currently performing. Over recent periods, the company has seen revenue move from US$6.13b on a trailing basis in FY 2025 to US$7.21b in FY 2026, while trailing EPS shifted from US$5.17 to US$5.28. This gives investors a clearer view of how top line scale and per share...

If you are wondering whether Grab Holdings is attractively priced at its current level, this article will walk through what the latest data suggests about its valuation. The stock most recently closed at US$4.22, with returns of 3.7% decline over 7 days, 6.8% decline over 30 days, 16.9% decline year to date, 13.0% decline over 1 year, 28.7% over 3 years and 63.4% decline over 5 years, which may prompt questions about how the market is reassessing its potential and risks. Recent coverage...

Why Quest Diagnostics is on investors’ radar today Quest Diagnostics (DGX) is drawing attention after recent share price moves, with the stock last closing at $211.91 and showing double digit total returns over the past year and past 3 months. See our latest analysis for Quest Diagnostics. The recent share price strength, including a 15.96% 1 month share price return and 21.93% year to date share price return, sits alongside a 1 year total shareholder return of 24.84%. This points to momentum...

In February 2026, State Street Investment Management launched five actively managed State Street MyIncome target-maturity high-yield corporate bond ETFs maturing between 2027 and 2031, while State Street Corporation declared cash dividends on its common and multiple preferred stock series payable in March and April 2026. This combination of new income-focused ETFs and ongoing preferred and common dividends highlights State Street’s effort to broaden fee-based products while continuing cash...

With no single headline event driving today’s move, Credit Acceptance (CACC) is drawing attention as investors weigh its recent share performance and current valuation signals in relation to the company’s latest reported fundamentals. See our latest analysis for Credit Acceptance. At a share price of $473.18, Credit Acceptance has seen a 9.17% 1 month share price return and a 4.24% year to date share price return, while its 1 year total shareholder return decline of 3.90% and 5 year total...

Eastman Chemical (NYSE:EMN) has completed a major fixed-income offering of unsecured notes with a fixed coupon and long maturity. The new issuance adjusts the company’s capital structure and adds a long term funding source to its balance sheet. This move has implications for liquidity, interest costs, and how Eastman approaches future borrowing and investment decisions. For investors watching NYSE:EMN, this bond deal comes after a mixed share price track record, with the stock at $75.51 and...

In recent months, e.l.f. Beauty has accelerated customer‑driven product launches via TikTok Live, expanded its hit Glow Reviver lip balm line with a limited‑edition dill pickle flavor, raised its fiscal 2026 revenue guidance on stronger‑than‑expected Rhode performance, and drawn both a fiduciary‑duty investigation and shifting short‑interest levels. Taken together, these developments highlight how e.l.f. is leaning on rapid innovation, social‑media engagement, and the Rhode acquisition...

Palomar Holdings (PLMR) recently filed a shelf registration for up to US$125.05 million in common stock, covering 1,035,613 shares. This filing gives the insurer flexibility to issue equity for future ESOP related initiatives. See our latest analysis for Palomar Holdings. Against this backdrop, Palomar’s 1 day share price return of 1.53% and recent 30 day gain of 3.35% contrast with a softer year to date share price return of 6.15% and a 1 year total shareholder return of 3.85%. At the same...

Incyte (INCY) is back in focus after Eli Lilly and Incyte received a positive opinion from the European Medicines Agency for extending Olumiant to adolescents with severe alopecia areata, marking a new regulatory milestone for the partnership. See our latest analysis for Incyte. While the latest EMA opinion has put Incyte back in the headlines, the share price has been relatively steady in the short term, with recent 1 day and 30 day share price returns close to flat. However, the 1 year...

Agilent Technologies (NYSE:A) received FDA approval for its PD-L1 IHC 22C3 pharmDx as the only authorized companion diagnostic for certain ovarian and related cancers treated with KEYTRUDA. The approval covers use of the assay to help identify patients who may be eligible for KEYTRUDA based on PD-L1 expression. The decision expands the clinical indications for PD-L1 IHC 22C3 pharmDx within Agilent's broader oncology diagnostics portfolio. For investors, this news sits at the intersection of...

Earlier this week, Teradata announced it had entered into a settlement agreement with SAP, under which SAP will pay US$480 million to resolve all past and pending litigation related to alleged trade secret misappropriation, leaving Teradata with an expected net cash benefit of about US$355 million to US$362 million before taxes. This settlement not only removes a major legal uncertainty but also gives Teradata additional financial flexibility at a time when its cloud ARR grew 15% and it...

Diebold Nixdorf (NYSE:DBD) has named Jeffrey Sesplankis as its principal accounting officer. Sesplankis succeeds Thomas S. Timko in this key finance and reporting role. Diebold Nixdorf, known for its ATM, payments and retail technology solutions, sits at the intersection of banking infrastructure and physical commerce. For investors, changes in senior finance roles can matter as much as product announcements, because they speak to how the company manages its books, oversees internal...

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax in locally advanced pancreatic cancer and has started commercial launch. The approval extends the company’s Tumor Treating Fields technology beyond its historic focus in glioblastoma into a new oncology market. NovoCure also announced a new CEO and a reorganization of its clinical team alongside the launch. NovoCure now trades around $13.67, with the stock up 20.3% over the past week and 8.7% over the past month, while longer...

Teladoc Health (TDOC) is back in focus after reporting fourth quarter and full year 2025 results, updating its 2026 outlook, and adding experienced finance executive Michael S. Smith to its board. See our latest analysis for Teladoc Health. Teladoc Health’s recent earnings update, 2026 guidance and board appointment come against a weak backdrop, with a 7 day share price return of 10.97% contrasting with a 30 day share price return of 8.36% and a 1 year total shareholder return decline of...

If you are wondering whether McGrath RentCorp at around US$110.67 is offering good value today, you are not alone. This article is built to help you weigh up what that price really represents. The stock is up 5.2% year to date. However, it has seen a 1.9% decline over the last week, a 5.7% decline over the last month and a 7.7% decline over the last year, which can change how the market is viewing its potential and risk. Recent coverage has focused on McGrath RentCorp's position in equipment...

In late February 2026, Synthekine announced a collaboration and supply agreement with Merck to test STK-012 alongside Keytruda and chemotherapy in the ongoing global Phase 2 SYNERGY-101 trial for first-line, PD-L1 negative nonsquamous non-small cell lung cancer. This agreement underlines Merck’s push to extend Keytruda’s reach in difficult-to-treat lung cancer while sharing development risk and keeping full rights to its own therapy. We’ll now examine how Merck’s expanded Keytruda...

International Bancshares (IBOC) has just wrapped up FY 2025 with fourth quarter total revenue of US$212.2 million and basic EPS of US$1.72, alongside net income of US$106.9 million. Trailing twelve month revenue came in at US$827.1 million with EPS of US$6.63 and net income of US$412.3 million. Over recent quarters the company has seen revenue move from US$203.2 million in Q3 2024 to US$216.3 million in Q3 2025, with quarterly EPS ranging from US$1.56 in Q1 2025 to US$1.74 in Q3 2025. This...

Stagwell’s Harris Poll unit has launched Harris QuestRQ, an always-on reputation intelligence platform. The new tool is designed to give businesses real-time tracking of brand reputation and related insights. The launch adds a fresh product to Stagwell’s marketing and communications offering under ticker NasdaqGS:STGW. For investors watching NasdaqGS:STGW, the Harris QuestRQ launch lands at a time when the stock has been volatile, with a 23.4% decline over the past 30 days and a 25.7%...

Yum! Brands recently reported that it paid no U.S. federal income tax on US$1.00 billion of pretax profits last year after shifting certain Pizza Hut intellectual property to Malta and is now reviewing options for its underperforming Pizza Hut division, including a potential sale and closure of about 250 weaker outlets. This reassessment comes as Taco Bell and KFC generate around 90% of Yum!’s operating profits, raising questions about how repositioning Pizza Hut could change the balance of...

If you are wondering whether W. P. Carey is reasonably priced or offering value today, comparing its current share price with fair value estimates is a useful place to start. The stock most recently closed at US$74.65, with returns of 3.1% over 7 days, 9.9% over 30 days, 15.1% year to date, 23.0% over 1 year, 10.9% over 3 years and 50.5% over 5 years. This gives some context for how the market has been reassessing it over different time frames. Recent coverage has focused on W. P. Carey as a...

Sportradar Group (NasdaqGS:SRAD) expanded its partnership with Super Technologies to supply its full suite of betting solutions across regulated European markets and support entry into Brazil. The company signed a multi year agreement with NBC Sports Regional Sports Networks to power AI driven real time broadcast features for live NBA coverage. Sportradar Group, trading at $18.26, operates at the intersection of sports data, betting services, and media. The stock is up 2.8% over the past...

Recently, CNBC host Jim Cramer highlighted Generac Holdings’ shift from a business-to-consumer focus toward business-to-business customers, emphasizing its role in supplying backup generators, battery storage systems, and smart home energy solutions amid a period of fewer natural-disaster-driven sales. His characterization of Generac as moving “from the moon to the stars” underscores how strongly some commentators view the company’s business model transition and growth potential beyond...

Why Masco is on investors’ radar today Masco (MAS) has caught attention after a period where the share price showed mixed moves, with a small 1 day decline, a pullback over the past week, yet gains over the past month and past 3 months. See our latest analysis for Masco. At a share price of US$71.62, Masco’s recent pullback, including a 1 day share price return of 1.08% decline and 7 day share price return of 4.7% decline, sits against a year to date share price return of 11.09% and a 3 year...